lymphopoiesis culture system
Immusoft’s core technology is the ex vivo lymphopoiesis culture system termed Immune System Programming (ISP™) technology. The culture system reliably and reproducibly differentiates autologous (patient-derived) cells into mature plasmablasts and plasma cells.These cells are capable of becoming long-lived and of sustainably producing the desired therapeutic protein at high concentrations.
Immusoft has an exclusive license option to the original culture system developed in the Lab of Dr. David Baltimore at the California Institute of Technology (Caltech). Extensive modifications made by Immusoft to the Baltimore culture system, have resulted in a number of filed patents to protect the core ISP™ technology.